

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BEUVINK ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/001849

FILED: 22 FEBRUARY 2005

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH
MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC
AGENT

MS: PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION


\ Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909

Date: *August 22, 2006*


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661